Author

J. L. Bell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Organism:mouse· 1

Frequent Co-Authors

D. Mercatelli· 1 shared D. Misiak· 1 shared D. Ziegler· 1 shared E. Ghazy· 1 shared E. Kasiou· 1 shared E. M. Poursani· 1 shared E. Valli· 1 shared F. M. Giorgi· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

D. Mercatelli

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

IGF2BP1 induces high-risk neuroblastoma and forms a druggable feedforward loop with MYCN promoting 17q oncogene expression

S. Hagemann, D. Misiak, J. L. Bell, T. Fuchs, M. I. Lederer, N. Bley, M. Haemmerle, E. Ghazy, W. Sippl, J. H. Schulte, S. Huettelmaier

This paper identifies a druggable feedforward loop between IGF2BP1 and MYCN in high-risk neuroblastoma that promotes oncogene expression and relapse, suggesting combined targeting as a therapeutic strategy.

bioRxiv · Mar 18, 2023Cancer Biology

Copper chelation inhibits TGF-β pathways and suppresses epithelial-mesenchymal transition in cancer

E. M. Poursani, D. Mercatelli, P. Raninga, J. L. Bell, F. Saletta, F. V. Kohane, Y. Zheng, J. Rouaen, T. R. Jue, F. T. Michniewicz, E. Kasiou, M. Tsoli, G. Cirillo, S. Waters, T. Shai-Hee, , O. VITTORIO

This paper shows copper chelation inhibits TGF-β pathways and reduces EMT in cancer cells, potentially offering a new therapeutic strategy for targeting TGF-β in cancer.

bioRxiv · Oct 3, 2022 · PreprintCancer Biology